Sign In
Buy ANIP
$75.23
+0.580 (+0.777%)
At Close: Jun 03, 2026
ANI (ANIP) Reports Q2 Earnings: What Key Metrics Have to Say
10:42am, Wednesday, 09'th Aug 2023
While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wal
ANI Pharmaceuticals (ANIP) Beats Q2 Earnings and Revenue Estimates
09:58am, Wednesday, 09'th Aug 2023
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.13 per share a year ago.
ANI Pharmaceuticals (ANIP) to Post Q2 Earnings: What's in Store?
12:38pm, Monday, 31'st Jul 2023
ANI Pharmaceuticals' (ANIP) second-quarter 2023 performance is likely to have been driven by rising generic and rare disease product revenues.
ANI Pharmaceuticals to Discuss Second Quarter 2023 Financial Results on August 9, 2023, at 8:30 a.m. ET
07:17am, Monday, 31'st Jul 2023
BAUDETTE, Minn., July 31, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2023 finan
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
11:21am, Tuesday, 18'th Jul 2023
Here is how ANI Pharmaceuticals (ANIP) and ImmunoGen (IMGN) have performed compared to their sector so far this year.
ANI Pharmaceuticals Is Undervalued When Considering Their Unadvertised Pipeline
12:51am, Wednesday, 05'th Jul 2023
ANIP Pharmaceuticals has not yet published a pipeline of products under development or out-licensed, leaving investors in the dark about future revenue opportunities. The company has a range of drugs
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
11:06am, Thursday, 22'nd Jun 2023
Here is how ANI Pharmaceuticals (ANIP) and Cardiol Therapeutics Inc. (CRDL) have performed compared to their sector so far this year.
ANI Pharmaceuticals: Strong Revenue Growth And ANDA Approvals
09:12pm, Tuesday, 30'th May 2023
ANI Pharmaceuticals exceeded Q1 Non-GAAP earnings expectations and raised its guidance to $385-$410 million. The company has a diverse product portfolio and strong relationships in the generic drug ma
ANI Pharmaceuticals to Present at the Jefferies Healthcare Conference
04:05pm, Monday, 22'nd May 2023
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer
ANI Pharmaceuticals (ANIP) Beats Q1 Earnings and Revenue Estimates
09:08am, Monday, 08'th May 2023
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.17 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to loss of $0.12 per share a year ago.
New Strong Sell Stocks for March 13th
11:06am, Monday, 13'th Mar 2023 Zacks Investment Research
ANIP, ARCB and ARCE have been added to the Zacks Rank #5 (Strong Sell) List on March 13, 2023.
New Strong Sell Stocks for March 13th
08:26am, Monday, 13'th Mar 2023
ANIP, ARCB and ARCE have been added to the Zacks Rank #5 (Strong Sell) List on March 13, 2023.
ANI Pharmaceuticals (ANIP) Q4 Earnings and Revenues Top Estimates
01:05pm, Thursday, 09'th Mar 2023 Zacks Investment Research
ANI (ANIP) delivered earnings and revenue surprises of 11.76% and 8.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) Q4 Earnings and Revenues Top Estimates
09:11am, Thursday, 09'th Mar 2023
ANI (ANIP) delivered earnings and revenue surprises of 11.76% and 8.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: Should You Buy?
03:00pm, Thursday, 02'nd Mar 2023 Zacks Investment Research
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
